Investigational drug · Phase 2
TRL1068
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee.
Phase 2Last checked: Nov 19, 2026Latest source record: May 7, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "TRL1068"
First trial start
2025
Apr 8, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TRL1068", any sponsor or status.
Conditions studied
As listed on its trial records.
- Prosthetic Joint Infections of Hip
- Prosthetic Joint Infections of Knee
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "TRL1068" as an intervention, largest first.
- Study to Evaluate the Efficacy and Safety of TRL1068 for the Treatment of Prosthetic Joint InfectionActive, not recruiting
Trellis Bioscience LLCIndustry
NCT06621251 · 60 participants (planned) · Start Apr 8, 2025 · Primary completion Apr 2027
Drug: TRL1068 (calpurbatug), a human monoclonal antibody · For: Prosthetic Joint Infections of Hip; Prosthetic Joint Infections of Knee
Sites: Gilbert, Arizona; Los Angeles, California; Jacksonville, Florida · 11 sites in all
Trellis Bioscience LLCIndustry
NCT04763759 · 15 participants · Start Feb 8, 2021 · Primary completion Mar 13, 2024
Drug: TRL1068, a human monoclonal antibody · For: Prosthetic Joint Infection
Sites: Birmingham, Alabama; Los Angeles, California; Santa Monica, California · 9 sites in all
Trellis Bioscience LLCIndustry
NCT07644195 · 14 participants (planned) · Start Oct 2026 · Primary completion Dec 2026
Drug: TRL1068, a human monoclonal antibody · For: Healthy Volunteer
Sites: Lincoln, Nebraska
Trellis Bioscience LLCIndustry
NCT05355207 · 12 participants (planned) · Start Jan 2024 · Primary completion Jan 2025
Drug: TRL1068 · For: Chronic Rhinosinusitis With Nasal Polyps
Newest research
PubMed records naming it or its code names, newest first.
- Novel Technologies in Periprosthetic Joint Infections: Emerging Therapeutics.
Magruder ML, Heckmann ND, Lieberman JR, et al. · J Arthroplasty 2026
- Antibiotics and non-traditional antimicrobial agents for carbapenem-resistant Acinetobacter baumannii in Phase 1, 2, and 3 clinical trials.
Kontogiannis DS, Romanos LT, Tzvetanova ID, et al. · Expert Opin Investig Drugs 2025
- Antibiotics and non-traditional antimicrobial agents for Pseudomonas aeruginosa in clinical phases 1, 2, and 3 trials.
Romanos LT, Kontogiannis DS, Tsiampali C, et al. · Expert Opin Investig Drugs 2025
- Phase 1 study of the pharmacokinetics and clinical proof-of-concept activity of a biofilm-disrupting human monoclonal antibody in patients with chronic prosthetic joint infection of the knee or hip.
Conway J, Delanois RE, Mont MA, et al. · Antimicrob Agents Chemother 2024
- Monoclonal Antibody Disrupts Biofilm Structure and Restores Antibiotic Susceptibility in an Orthopedic Implant Infection Model.
Burke ZDC, Hart CM, Kelley BV, et al. · Antibiotics (Basel) 2023
- Human antibody repertoire frequently includes antibodies to a bacterial biofilm associated protein.
Ryser S, Tenorio E, Estellés A, et al. · PLoS One 2019
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.